New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
AcelRx Pharmaceuticals, Inc.
ACRX
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

15M

Drug Manufacturers - Specialty & Generic

Next Earning date - 06 Nov 2024

15M

Drug Manufacturers - Specialty & Generic

Next Earning date - 06 Nov 2024

0.86USD
Shape0.06 ( 7.50%)
favorite-chart

Relative Strenght

93
favorite-chart

Volume Buzz

74%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

63%

Quote Panel

Shape
Updated October 28, 2024
1W % 1M % 3M % 1Y 80.78 %

Key Metrics

Shape
  • Market Cap

    14.58M


  • Shares Outstanding

    16.95M


  • Share in Float

    12.03M


  • Dividende

    0


  • Earning Date

    06 Nov 2024


  • Price Target

    0.86


  • Average Volume

    138824


  • Beta

    0.517


  • Range

    0.425-2.3


  • Industry

    Drug Manufacturers - Specialty & Generic


  • Website

    https://www.acelrx.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

23.44x

P/S Ratio

0.79x

P/B Ratio

0.0

Debt/Equity

-1266.1%

Net Margin

$-2.8

EPS

How ACRX compares to sector?

P/E Ratio

Relative Strength

Shape

ACRX

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$3M

Shape267%

2025-Revenue

$0.90

Shape3%

2025-EPS

$3M

Shape-267%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

H.C. Wainwright

upgrade

Previous: Not converted

2023-08-18

Now: Buy

Earnings GrowthShape

status-upYoY

Current

Estimates

Q4.21

arrow
arrow

N/A

-1.20
vs -2.00

Q1.22

arrow
arrow

N/A

-1.20
vs -1.60

Q2.22

arrow
arrow

N/A

-1.20
vs -1.60

Q3.22

arrow
arrow

N/A

-0.94
vs -1.40

Q4.22

arrow
arrow

N/A

-1.01
vs -1.20

Q1.23

arrow
arrow

+183%

1
vs -1.20

Q2.23

arrow
arrow

N/A

-0.41
vs -1.20

Q3.23

arrow
arrow

N/A

-0.08
vs -0.94

Q4.23

arrow
arrow

N/A

-0.25
vs -1.01

Q1.24

arrow
arrow

+58%

1.58
vs 1

Sales GrowthShape

status-upYoY

Current

Estimates

Q4.21

arrow
arrow

-100%

2K  vs 738K

Q1.22

arrow
arrow

-13%

442K  vs 511K

Q2.22

arrow
arrow

+29%

570K  vs 443K

Q3.22

arrow
arrow

-73%

507K  vs 1.9M

Q4.22

arrow
arrow

+12500%

252K  vs 2K

Q1.23

arrow
arrow

-100%

NA  vs 442K

Q2.23

arrow
arrow

-56%

253K  vs 570K

Q3.23

arrow
arrow

-77%

117K  vs 507K

Q4.23

arrow
arrow

-44%

140K  vs 252K

Q1.24

arrow
arrow

NA

442.8K  vs NA

Return on EquityShape

status-upQoQ

Q4.21

arrow
arrow

+22%

0.22
vs 0.19

Q1.22

arrow
arrow

+22%

0.22
vs 0.22

Q2.22

arrow
arrow

+213%

2.13
vs 0.22

Q3.22

arrow
arrow

-25%

-0.25
vs 2.13

Q4.22

arrow
arrow

-34%

-0.34
vs -0.25

Q1.23

arrow
arrow

+37%

0.37
vs -0.34

Q2.23

arrow
arrow

-42%

-0.42
vs 0.37

Q3.23

arrow
arrow

-7%

-0.07
vs -0.42

Institutionnal OwnershipShape

status-upQoQ

Q1.21

arrow
arrow

86

86
vs 79

9%

Q2.21

arrow
arrow

75

75
vs 86

-13%

Q3.21

arrow
arrow

60

60
vs 75

-20%

Q4.21

arrow
arrow

60

60
vs 60

NA

Q1.22

arrow
arrow

48

48
vs 60

-20%

Q2.22

arrow
arrow

53

53
vs 48

10%

Q3.22

arrow
arrow

48

48
vs 53

-9%

Q4.22

arrow
arrow

1

1
vs 48

-98%

Earnings Growth

Latest News